World's Best Scientists 2026 revealed!
Jesús F. San Miguel

Jesús F. San Miguel

Award Badge
Medicine
Spain
2026

D-Index & Metrics

Medicine

D-Index
163
Citations
129019
World Ranking
673
National Ranking
5

Jesús F. San Miguel publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jesús F. San Miguel sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,402 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jesús F. San Miguel D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jesús F. San Miguel sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 163 D-Index — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in Spain Leader Award
  • 2025 - Research.com Medicine in Spain Leader Award
  • 2023 - Research.com Medicine in Spain Leader Award

Overview

Jesús F. San Miguel is affiliated with the University of Navarra in Spain and has contributed extensively to research in medicine, with a particular focus on hematology, molecular biology, and oncology. Their work spans multiple specialized subfields including hematology, molecular biology, oncology, genetics, and radiology, nuclear medicine, and imaging.

The scientist's main topics of research include:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • CAR-T cell therapy research
  • Peptidase Inhibition and Analysis
  • Monoclonal and Polyclonal Antibodies Research
  • Chronic Lymphocytic Leukemia Research
  • Cancer Treatment and Pharmacology

Jesús F. San Miguel has published several recent papers in prominent medical journals. Notable publications include:

  • Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma, 2023, New England Journal of Medicine
  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma, 2021, New England Journal of Medicine
  • Teclistamab in Relapsed or Refractory Multiple Myeloma, 2022, New England Journal of Medicine
  • The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee, 2022, Blood
  • Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology

The scientist collaborates frequently with other researchers in the field. Some of their frequent co-authors include María-Victoria Mateos, Bruno Paiva, Joaquin Martínez-López, Albert Oriol, and Paula Rodríguez-Otero.

Jesús F. San Miguel's research has been published predominantly in high-impact journals, with the most frequent publication venues being Blood, Journal of Clinical Oncology, Clinical Lymphoma Myeloma & Leukemia, HemaSphere, and Blood Cancer Journal.

They have also contributed to book publications, including one with Springer Nature (Netherlands) titled Advances in Italian Mechanism Science, published in 2020.

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • International staging system for multiple myeloma.

    Philip R. Greipp;Jesus San Miguel;Brian G.M. Durie;John J. Crowley

  • International uniform response criteria for multiple myeloma

    B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade

  • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

    Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin

  • Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

    Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

    Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Meletios Dimopoulos;Andrew Spencer;Michael Attal;H. Miles Prince

  • Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

    Xose S. Puente;Magda Pinyol;Víctor Quesada;Laura Conde

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C Munshi;Larry D Anderson;Nina Shah;Deepu Madduri

  • Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Meletios A. Dimopoulos;Albert Oriol;Hareth Nahi;Jesus San-Miguel

  • Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

    Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo

  • Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

    S. Vincent Rajkumar;Jean Luc Harousseau;Brian Durie;Kenneth C. Anderson

  • A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

    Pierre Fenaux;Claude Chastang;Sylvie Chevret;Miguel Sanz

  • Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

    Roger G. Owen;Steven P. Treon;Ayad Al-Katib;Rafael Fonseca

  • Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson

  • Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

    Jesús F. San-Miguel;Vânia T.M. Hungria;Sung Soo Yoon;Meral Beksac

  • Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

    Jesús Fernando San Miguel;Jesús Fernando San Miguel;Katja Weisel;Philippe Moreau;Martha Lacy

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

    S. K. Kumar;J. H. Lee;J. J. Lahuerta;G. Morgan

Frequent Co-Authors

Maria-Victoria Mateos
Maria-Victoria Mateos University of Salamanca
Joan Bladé
Joan Bladé University of Barcelona
Alberto Orfao
Alberto Orfao University of Salamanca
Ramón García-Sanz
Ramón García-Sanz University of Salamanca
Juan José Lahuerta
Juan José Lahuerta Complutense University of Madrid
Albert Oriol
Albert Oriol Autonomous University of Barcelona
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Paul G. Richardson
Paul G. Richardson Harvard University
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Antonio Palumbo
Antonio Palumbo University of Turin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Thinking about expanding your career options beyond a traditional medical path? There are a variety of online healthcare degrees and career pathways that may align with your interests and goals.

For those interested in mental health, consider enrolling in one of the fastest pmhnp program options, which offer a quicker route to a specialized Nurse Practitioner role. If your passion lies in leadership and management, an affordable healthcare administration degree online can open doors to administrative roles in hospitals, clinics, or health organizations.

Looking to advance further? Explore some of the cheapest mha online programs for a cost-effective way to earn your Master's in Healthcare Administration. For nurses seeking the highest clinical credentials, there are also dnp online programs cheap, allowing you to become a Doctor of Nursing Practice at an affordable price.

Each program offers unique advantages, making it easier to find a pathway that fits your schedule, budget, and long-term career vision.

Best Scientists Citing Jesús F. San Miguel

Trending Scientists

Recently Published Articles